The Current Ratio as of December 2024 (TTM) for Outlook Therapeutics, Inc. (OTLK) is 1.07

According to Outlook Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.07. This represents a change of 32.06% compared to the average of 0.81 of the last 4 quarters.

Outlook Therapeutics, Inc. (OTLK) Historical Current Ratio (quarterly & annually)

How has OTLK Current Ratio performed in the past?

The mean historical Current Ratio of Outlook Therapeutics, Inc. over the last ten years is 0.81. The current 1.07 Current Ratio has changed 13.10% with respect to the historical average. Over the past ten years (40 quarters), OTLK's Current Ratio was at its highest in in the December 2022 quarter at 4.09. The Current Ratio was at its lowest in in the December 2014 quarter at 0.

Outlook Therapeutics, Inc. (OTLK) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Outlook Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Outlook Therapeutics, Inc. (OTLK) Average Current Ratio

How has OTLK Current Ratio performed in the past?

The current Current Ratio of Outlook Therapeutics, Inc. (OTLK) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Outlook Therapeutics, Inc. (OTLK) Current Ratio vs. Peers

How is OTLK’s Current Ratio compared to its peers?

Outlook Therapeutics, Inc.’s Current Ratio is greater than Checkpoint Therapeutics, Inc. (0.29), greater than Mustang Bio, Inc. (0.40), greater than Reviva Pharmaceuticals Holdings, Inc. (0.39), less than Fortress Biotech, Inc. (1.23), less than Kodiak Sciences Inc. (8.42), less than Ocuphire Pharma, Inc. (10.68), less than Protalix BioTherapeutics, Inc. (1.98), less than EyePoint Pharmaceuticals, Inc. (5.50), less than SELLAS Life Sciences Group, Inc. (2.26), greater than Eyenovia, Inc. (0.74), less than Cidara Therapeutics, Inc. (3.54), less than Fortress Biotech, Inc. (1.23), less than Selecta Biosciences, Inc. (1.33), less than X4 Pharmaceuticals, Inc. (4.89), less than Inozyme Pharma, Inc. (7.68), less than Terns Pharmaceuticals, Inc. (32.99), less than Day One Biopharmaceuticals, Inc. (14.62), less than HOOKIPA Pharma Inc. (3.26), less than Heron Therapeutics, Inc. (2.28), less than Galera Therapeutics, Inc. (9.74),

Build a custom stock screener for Outlook Therapeutics, Inc. (OTLK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Outlook Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Outlook Therapeutics, Inc. (OTLK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Outlook Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.